Xmab®808, Keytruda® (Pembrolizumab)
Urothelial Carcinoma, Colorectal Cancer, Head And Neck Squamous Cell Carcinoma, Castration-Resistant Prostate Cancer, Tnbc - Triple-Negative Breast Cancer, Melanoma Excluding Uveal Melanoma, Non-Small Cell Lung Cancer, Squamous Or Non-Squamous, Renal Cell Carcinoma, Clear Cell, Ovarian Cancer, Epithelial
Completed
Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors
―